|
Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC
NU 2023-113
INVENTORS
Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Reuben Shaw (Salk Institute)
SHORT DESCRIPTION
A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden.
BACKGROUND
Lung...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s): Reuben Shaw
Keywords(s): Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics.
NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036)
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
SHORT DESCRIPTION
MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders.
BACKGROUND
Leukemia and brain...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 COMPASS mutant cancer
NU 2022-053
INVENTORS
Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
SHORT DESCRIPTION
A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION
Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma.
INVENTORS
Amy Heimberger*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
* Principal Investigator
NU 2025-212
IP...
Published: 4/29/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms
SHORT DESCRIPTION
Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs).
NU Tech IDs: NU 2018-169, NU 2021-005
PRINCIPAL INVESTIGATOR
Peng Ji
Northwestern University Feinberg School of Medicine, Department of Pathology
IP...
Published: 4/16/2026
|
Updated: 4/16/2026
|
Inventor(s):
Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Anti-CD73 Monoclonal Antibody for Enhanced Cancer Immunotherapy
NU 2020-207
INVENTORS
Bin Zhang*
Siqi Chen
Jie Fan
SHORT DESCRIPTION
This invention comprises novel anti-CD73 monoclonal antibody compositions that recognize and inhibit mouse and human CD73.
BACKGROUND
CD73, an ecto-enzyme associated with adenosine metabolism, is an emerging immune checkpoint that promotes tumor progression by suppressing...
Published: 12/11/2025
|
Updated: 1/30/2025
|
Inventor(s):
Keywords(s): Brain cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Immunotherapy, Lung cancer, Ovarian cancer, Pancreatic cancer, Therapeutics
Category(s): Life Sciences > Therapeutics
|